# Shenzhen Shenxin Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shenzhen-shenxin-biotechnology-co

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Website: www.innorna.com
- Total disclosed funding: $120M
- Latest round: Series B (Mar 28, 2022)
- Investors on record: 12

## About

Established in 2019 and based in Shenzhen, China, Shenzhen Shenxin Biotechnology Co., Ltd. is a biotechnology company that focuses on research and development of core mRNA delivery technology. The company has completed 3 rounds of funding as of 2022. The company has set up biotech R&D labs in Shenzhen, Nanjing and Hong Kong. Dr. Linxian Li, the company's founder and CEO, holds a PhD from the University of Heidelberg, Germany, was a postdoctoral fellow at MIT, and is currently an assistant professor at Karolinska School of Medicine. The company has an R&D and CMC team of nearly 200 people and a 4500 square meter R&D lab.

The company is engaged in the development of novel preventive and therapeutic vaccines and drugs based on mRNA technology and LNP delivery technology. The company has four major R&D pipelines include infectious disease vaccines, rare diseases, therapeutic oncology vaccines, and oncology immunotherapy boosters.

## Funding rounds

- Series B, Mar 28, 2022, $120M — CDH Investments, CPE Funds Management, China Renaissance, E Fund Overseas Investment, BOCG, Fangyuan Capital (Hong Kong) Limited, Hainan Huayi Private Equity Fund Management
- Series A, Jul 23, 2021 — Legend Capital, CPE Funds Management, Casstar Capital, Lanting Capital, Dynamic Capital, Qianhai Ark Capital
- Angel, Nov 22, 2020 — Casstar Capital, Lanting Capital, Dynamic Capital, Qianhai Ark Capital

## Investors

- Casstar Capital (https://capitalatlas.ai/funds/casstar-capital) — Angel, Series A
- Lanting Capital (https://capitalatlas.ai/funds/lanting-capital) — Angel, Series A
- Dynamic Capital (https://capitalatlas.ai/funds/dynamic-capital) — Angel, Series A
- Qianhai Ark Capital (https://capitalatlas.ai/funds/qianhai-ark-capital) — Angel, Series A
- Legend Capital — Series A
- CPE Funds Management (https://capitalatlas.ai/funds/cpe-funds-management) — Series A, Series B
- CDH Investments (https://capitalatlas.ai/funds/cdh-investments) — Series B
- China Renaissance (https://capitalatlas.ai/funds/china-renaissance) — Series B
- E Fund Overseas Investment (https://capitalatlas.ai/funds/e-fund-overseas-investment) — Series B
- BOCG (https://capitalatlas.ai/funds/bocg) — Series B
- Fangyuan Capital (Hong Kong) Limited (https://capitalatlas.ai/funds/fangyuan-capital-hong-kong-limited) — Series B
- Hainan Huayi Private Equity Fund Management (https://capitalatlas.ai/funds/hainan-huayi-private-equity-fund-management) — Series B